Introduction
Patients with adult Ph-pos ALL in whom the Ph chromosome-a reciprocal translocation between chromosomes 9 and 22 resulting in a bcr-abl fusion gene and consequent oncoprotein with enhanced tyrosine kinase activity-is detected, either by conventional cytogenetics, FISH or molecular detection of bcr-abl 1 constitute the largest, clearly defined subgroup of ALL. Ph-pos ALL represents approximately one-fifth to one-quarter of adult patients with ALL. 2 In children, Ph-pos ALL is much less common. 3 Different breakpoints in the bcr gene, major and minor, produce fusion genes resulting in either a 210 or a 190 KDa protein 4 respectively. It appears that major breakpoint fusions (p210) originate in haematopoietic stem cells, whereas minor breakpoint fusions (p190) have a Bcell progenitor origin, suggesting that p190 ALL and p210 Ph-pos ALL may be distinct biological and clinical entities. 5 The poor prognostic relevance of having a Phpos leukaemia-whatever the fusion protein-is firmly established, in both adults and children. Although Ph-pos ALL does respond to combination chemotherapy, CR (less than 5% lymphoblasts as assessed by conventional light microscopy) after standard induction regimens is less likely to be achieved than in Ph-neg ALL. The disease is also distinguished by particularly short remission durationmedian event-free survival of 8 months-leading to a very poor prognosis overall, with 5-year overall survival (OS) with chemotherapy alone of 10-20%. 3, [6] [7] [8] [9] [10] It has long been concluded that standard combination chemotherapy alone is insufficient, in almost all cases, to cure Ph-pos ALL. In view of previous evidence of a GVL effect in ALL, and an increasing understanding that relapsed ALL in adults is almost untreatable, whatever the initial therapy, 11 sibling allogeneic haematopoietic stem cell transplantation (sib allo HSCT) has been extensively investigated in Ph-pos ALL. Most physicians would recommend sib allo HSCT for patients of suitable age and performance status with a matched donor who has achieved CR. Within clinical studies, Ph-pos ALL is regarded as 'very high risk' and patients-children as well as adults-are usually assigned to an HSCT arm. Table 1 gives a summary of what treatment is assigned for Ph-pos ALL in a range of current clinical studies.
A review of the practice of allo HSCT in Ph pos ALL is timely. The increasing use of unrelated donors, alternative sources of stem cells such as umbilical cord blood and the extension of eligibility for HSCT by the use of nonmyeloablative conditioning regimens all mean that HSCT is potentially much more widely available. In addition, the recent appearance of drugs with specific activity against the abl tyrosine kinase may also change the role of HSCT in Ph-pos ALL. By contrast with CML, where apparently durable molecular remissions resulting from tyrosine kinase inhibitors mean that HSCT is no longer the treatment of first choice, 12 it is probable that tyrosine kinase inhibitors will act as a 'bridge to transplant' in Ph-pos ALL, by helping more patients to achieve and maintain remission of sufficient duration to make HSCT feasible.
In reviewing currently available data, it is important to remember that Ph-pos ALL is not common. Smaller series addressing the issue of HSCT may often suffer from considerable selection bias. Large studies where analyses are carried out on an 'intention-to-treat' basis often take many years to conclude and require the participation of multiple centres. During the conduct of some of the larger studies, transplant practices and supportive care may have changed. Hence it is possible that treatment-related mortality (TRM) may not always be representative of what can be achieved currently. In many studies, specific conditioning regimens, GVHD prophylaxis and T-cell depletion (or not) were not specified. Sometimes, only the broadest interpretation of whether 'a transplant' is the right thing is possible. In addition, the interpretation of the definition of 'remission' must be carefully considered when interpreting data on Ph-pos ALL, since the possibility of achieving and documenting morphological, cytogenetic and molecular remission exists. Particularly within the area of non-myeloablative conditioning, accurate, quantitative documentation of disease status before and after HSCT is vital to help interpret the outcome data.
In this review we will (1) review available studies of sibling allo HSCT in Ph-pos ALL to reach the most specific conclusions possible regarding optimal transplant protocols and outcomes; (2) review evidence as to whether HSCT using matched unrelated donors (MUD) as a source of stem cells can be recommended in the absence of a sibling donor; (3) review outcomes using alternative sources of stem cells, for example, umbilical cord blood; (4) examine whether, for patients in whom myeloablative conditioning is not possible, non-myeloablative approaches hold promise and (5) review data regarding the remission rates and outcomes in patients with Ph-pos ALL who have received therapy with tyrosine kinase inhibitors in induction or consolidation and see how this might influence the practice of HSCT in this disease.
Can high-dose therapy and sibling HSCT overcome the adverse risk posed by presence of the Ph chromosome?
There are a number of studies of myeloablative therapy followed by sib allo HSCT that specifically relate to Ph-pos ALL. 10, [13] [14] [15] [16] The main features of these studies are listed in Table 2 . In summary, the data indicate that in selected individuals, disease-free survival (DFS) or OS appears better than would be expected with treatment with chemotherapy alone. The strongest support for this contention from published data comes from Dombret et al., where the existence of an allogeneic donor among those eligible for HSCT was independently predictive of remission duration. The largest prospective study of patients with Ph-pos ALL has been carried out by the in a UK-USA collaboration, UKALLXII/ECOG2993. The trial examined the role of HSCT in Ph-pos ALL by assigning all patients, wherever possible, to allo HSCT using etoposide and 13.2 Gy TBI as conditioning-in the absence of a sibling donor, a MUD was selected. The data have only been published in abstract form 17 but support the assignment of sibling donor HSCT to patients with Ph-pos ALL. A note of caution must be introduced based on the results of donor vs no donor analysis in patients with Phneg disease from the same multi-centre study. Extrapolating from the data on patients with Ph-neg ALL 18 it is likely that the high mortality of allo HSCT in 'older' patients will reduce the benefit. The age threshold above which regimenrelated death exceeds reduction in relapse risk is not clear in Ph-pos ALL. Again, extrapolating from data on Ph-neg disease, it may be as low as 35-40 years old.
The optimal conditioning regimen is not clear. The most commonly used regimens are cyclophosphamide and TBI or etoposide and TBI. A small study suggested no difference between the two regimens in childhood ALL. 19 However, there is some evidence from a comparative retrospective IBMTR study that etoposide might be superior to cyclophosphamide. If cyclophosphamide is used, a TBI dose of 13.2 Gy should be ensured. 20 
Table 1
Some ongoing studies in Ph pos ALL Overall, the weight of evidence suggests that myeloablative therapy, with a TBI-based conditioning regimen followed by sib allo HSCT represents the current best available treatment option for younger patients with Ph-pos ALL in CR1. It is not clear whether these age limits are fixed for myeloablative HSCT or will change with improvements in transplant practice.
Is fully matched unrelated donor HSCT following myeloablative conditioning a suitable alternative when no sibling donor is available?
Evidence on whether matched sibling stem cells are equivalent with MUD will always be subject to the inherent problem of analysing outcomes by treatment received, since there is no possibility of carrying out a randomization. One must also take into consideration that use of unrelated donor stem cells, even if inferior to sib allo HSCT in terms of treatment-related morbidity and mortality, might still be superior to chemotherapy alone in the management of Ph-pos ALL. However, there is accumulating evidence to suggest that patients receiving fully MUD stem cells have an equivalent outcome in terms of toxicity and TRM as those receiving sibling stem cells from matched siblings. It is almost impossible to conclude on the anti-leukaemia efficacy from any of the published data, since most of the studies are retrospective and involve a wide variety of patients, often those beyond CR1 and sometimes patients in frank relapse. The OS and DFS outcomes are necessarily poor due to selection. Comparison of TRM is perhaps the more important aspect of realistically assessing the data available. In a single-centre study of 84 patients with highrisk ALL, a considerable proportion beyond CR1, where almost all patients received a TBI-based conditioning regimen, TRM did not differ significantly between the two sources of stem cells. However, the median age of patients was only 23 years and the population included children. 21 A similar study including a larger number of patients (N ¼ 221, 72 of whom were Ph pos) and a median age more representative of an adult population 22 also showed no difference in TRM, both sources of stem cells giving equally high TRM matched sibling 43%, and unrelated donor HSCT 50%. Once again, patients beyond CR1 were included, which is likely to adversely influence the TRM. 23 In studies specifically relating to Ph-pos ALL, an initial small series of patients concluded that MUD allo HSCT was a viable option in the absence of a sib donor. 24 Arico et al. 25 in a large series of patients did not demonstrate a better outcome for MUD HSCT over chemotherapy in children with Ph-pos ALL due to the 43% TRM. There was, however, a low relapse rate (19%) among survivors. A larger but still retrospective study of patients with poor-risk ALL, 97 of whom were Ph pos showed a TRM of 54% but relapse mortality of only 6% in patients in CR1. Transplant in CR1 and a shorter interval from diagnosis to transplant was significant for improved survival by multivariate analysis. 26 The largest prospective study of an unrelated donor HSCT in de novo adult Ph-pos ALL was carried out in UKALLXII/ECOG2993. HSCT was carried out using a uniform conditioning regimen of etoposide and TBI. T-cell depletion either in vitro or in vivo was not recommended, but it was left to the discretion of the investigators. At 5 years, there was no statistically significant difference in OS or in cause of death between those receiving sib allo HSCT and those receiving MUD allo HSCT. Whereas the leading cause of death was relapse in chemotherapy-treated patients, the leading cause of death after allo HSCT was related to treatment. Data on how many transplants were carried out with some form of T-cell depletion are not yet available.
Regarding the role of T-cell depletion, there are few data that directly address this issue in this disease. However, a general viewpoint would be that the lower TRM seen after T-cell depletion is likely compensated by a higher relapse rate. Marks et al. 27 reported a relapse rate of 40% when using T-cell depletion, either by CD34 antibody selection or by administering alemtuzumab. Whether T-cell depletion can be 'finely tuned'-for example an optimum dose of alemtuzumab defined to balance the mortality caused by GVHD against the relapse risk-remains to be seen. Opinion is currently divided as to the best approach. Taken together, published data suggest that myeloablative therapy followed by an eight out of eight allelic matched unrelated donor HSCT is an appropriate therapy for Ph-pos ALL in CR1 and can be recommended in clinical practice or within treatment arms of multi-centre clinical trials for patients within carefully defined age limits. Considerable caution should be exercised in recommending myeloablative MUD HSCT in 'older' patients. A clear risk, benefit age cutoff-or other risk-related scoring systemhas not yet been defined for MUD HSCT in Ph-pos ALL.
Alternative sources of stem cells: mismatched unrelated donors, haploidentical donors and umbilical cord blood
Despite increasing size of donor pools, it is not possible to find an eight of eight allelic MUD for all individuals. Using donors who are not fully matched or turning to alternative sources of stem cells is an option which may be considered by transplant units, for patients with Ph-pos ALL.
To what extent do available data support these approaches?
In children, a recent, very large retrospective study comparing the outcomes of HSCT using marrow or cord blood was carried out in patients receiving MUD or umbilical cord blood HSCT for leukaemia. 28 Greater than 60% of those included had a diagnosis of ALL, mostly beyond CR1. TRM was highly statistically significantly higher after transplants of HLA-antigen mismatched umbilical cord blood compared to fully matched BM stem cells (relative risk 2.31 for two antigen mismatch, 1.88 for one antigen mismatch) although relapse rates were lower after two-antigen HLA-mismatched umbilical cord blood transplants (RR 0.54, P ¼ 0.0045). The authors conclude that the data support the use of HLA-matched and even one-or two-antigen HLA-mismatched umbilical cord blood in children with acute leukaemia who need transplantation. These data do not specifically address the issue of children with Ph-pos ALL in CR1, but the conclusion from this study may be relevant to this situation. The current pan-European trial in paediatric Ph-pos ALL (EsPhALL ; Table 1 ) allows the use of umbilical cord blood as a source of stem cells for the HSCT recommended for all children with donors.
In adults, due to the close relationship between cell dose and haematopoietic recovery/risk of TRM, a major limitation to the use of cord blood is the difficulty in obtaining sufficient numbers of haematopoietic precursor cells. An earlier report of umbilical cord blood HSCT in adults confirmed a higher TRM in adults compared to MUD HSCT, although MUD stem cells carried equivalent mortality to cord blood. 29 Currently, insufficient evidence exists to recommend the use of alterative sources of stem cells such as umbilical cord blood in adults with Ph-pos ALL in routine clinical practice, nor is the technology sufficiently ripe for investigation within large multi-centre studies. Nonetheless, it is likely that improving this technology with approaches to increase cells dose-by using, for example, dual-cord units-will ultimately yield a technique which is safe enough for wider investigation for application in Ph-pos ALL in adults.
HSCT using haploidentical donors is also a consideration in high-risk diseases such as Ph-pos ALL when MUDs are not found. Just over 60 cases relating to adult ALL have been reported upon since 1993, 15 of these cases were Ph pos, approximately half were beyond CR1. The data have been recently reviewed in detail. 30 Although the techniques have improved greatly, good results obtained by single centres have been almost impossible to replicate outside these very experienced settings due to the high TRM, stemming from both rejection and severe GVHD. It is not possible to recommend this approach for wider use at the current time.
Non-myeloablative conditioning
An obvious question arising from the situation in which a high TRM in certain patient groups is sufficient to overcome the benefit of any GVL effect is whether reducing the intensity of the conditioning regimen can restore the balance between toxicity and efficacy. It is clear that nonmyeloablative or reduced-intensity conditioning (RIC) regimens can deliver a powerful graft-vs-tumour effect in many diseases but the success of this approach likely relates to both disease burden and tempo of the underlying disease. A recent study of relapse risk in patients with various malignancies treated with RIC HSCT attests to the fact that the highest relapse risk is in those patients with advanced lymphoid and myeloid malignancies. 31 To date there are scant published data on the use of RIC HSCT conditioning in ALL. In a small study of 22 patients with ALL, 11 of whom had Ph-pos disease and most of whom were very high risk, many having relapse after previous myeloablative therapy was reported. 32 Not surprisingly, the only leukaemia-free survivors were among those individuals treated in CR. Martino et al. 33 reported another small retrospective series of 27 RIC HSCT-treated older patients (mean age 50), with high-risk ALL. Among them 41% were Ph-pos treated and 85% were beyond CR1. In this very high-risk group, 2-year TRM was 23% and 2-year OS was 31%. The low TRM and moderate OS suggest there may have been some survival benefit to the procedure that outweighed the toxicity. For ALL in CR2, a series of 43 RIC HSCT in both adults and children has recently been published from Mexico. 22 The regimen was chosen above myeloablative HSCT, partly for economic reasons. Only two of the patients were Ph pos. All patients became full donor chimeras, but in spite of this the relapse rate was high, in the order of 70%. OS at 3 years was 31%. However, outcome after relapse is known to be poor 11, 34 and this study does not preclude benefit to the procedure in earlier stages of the disease. It remains a reasonable hypothesis that patients with ALL at high risk of relapsing as well as at very high risk of TRM, could benefit from RIC HSCT if the disease is in 'remission' at the time of HSCT. The definition of 'remission' may be of crucial importance here. It is clear that detection of minimal residual disease (MRD) by bcr-abl predicts relapse in Ph-pos ALL. 35, 36 However, it is not clear whether RIC HSCT would be able to overcome the additional risk factor of having detectable MRD pre-HSCT. It will be interesting to observe if the depth of remission, that is being MRD negative as compared to being only in morphological CR or cytogenetic remission could alter the outcome. Whether donor lymphocyte infusions in combination with tyrosine kinase inhibitors 37 might be of value to treat patients with residual MRD post-RIC HSCT is also not clear. A planned UK-USA collaborative trial will evaluate RIC HSCT in older patients with Ph neg disease at highest risk of relapse.
The role of tyrosine kinase inhibitors
The abl-specific tyrosine kinase, imatinib, has now been extensively studied as an addition to the therapy of Ph-pos ALL. Unfortunately, there have been no randomized controlled studies comparing the outcome with imatinib vs no imatinib. An initial study demonstrated that imatinib could be used as salvage therapy in Ph-pos ALL, allowing some patients to reach HSCT who otherwise would not have been eligible. 38 In published, non-randomized studies of patients with de novo disease, imatinib appears to improve the CR rate, compared to historical controls. The CR rate in a Japanese Adult Leukemia Study Group (JALSG) was 96%, substantially and significantly higher than the 51% reported in their previous trial without imatinib. 39 However, 51% is low-by comparison, the CR rate in the MRCUKALLXII/ECOG 2993 study for Ph-pos ALL was 83% with chemotherapy alone. As a result of the high CR rate, 63% of patients in the JALSG study were treated with allo HSCT in CR1. The follow-up period was too short to reach conclusions about long-term benefit. A small series from the MD Anderson adding imatinib to hyper-CVAD induction also concluded superiority over chemotherapy alone. 40 Imatinib may also have a role to play post-HSCT. The most recently reported study of imatinib in induction from the French national group GRAALL supports the notion that the addition of imatinib to induction can increase the number of patients reaching HSCT. Imatinib was added to induction (early poor responders) or to consolidation (good early responders) and maintained until HSCT. In 45 patients, CR rate was 96%. Each one of the 22 patients reaching CR who had a donor actually received allogeneic SCT in first CR. Followup so far is short. Estimated OS 65% at 18 months. 41 Imatinib may also play a role in post-HSCT maintenance. In a study in which all patients with Ph-pos ALL who became bcr-abl positive after HSCT were given imatinib did show some long-term responses to those responding to imatinib. 42 However, there is evidence that imatinib alone, without HSCT or other active therapy, is unlikely to make a significant contribution to long-term OS. In a recent study in 55 older patients-median age 68, beyond the age at which HSCT is typically offered-imatinib was randomized between co-administration with induction chemotherapy or subsequent co-administration with consolidation chemotherapy. 43 The CR rates were 96 and 50% respectively. However, there was no significant difference between the two cohorts in OS. Median DFS was significantly longer in the 43% in whom bcr-abl transcripts became undetectable. Therefore, it appears that the initial benefit of imatinib in terms of improved CR rate does not translate into improved survival. In examining the mechanism for the lack of sustained efficacy with imatinib, Pfeifer et al. 44 reported that many patients harboured a small leukaemic clone with a kinase domain mutation at diagnosis. This was usually below the level of detection of direct cDNA sequencing. While the existence of this clone did not affect either the CR rate, there was a suggestion that relapse was considerably more frequent among patients presenting with kinase domain mutations.
There is also evidence that abnormal tyrosine kinase activity alone is not entirely responsible for the phenotype of Ph-pos ALL. Elegant models of CML and Ph-pos B-ALL developed in murine knockouts for three Src kinases Lyn, Hck and Fgr, showed that while these Src kinases are dispensable for the development of CML, they are absolutely required for the development of Ph-pos ALL. Thus, simultaneous inhibition of both tyrosine and Src kinases might hold out more promise that using tyrosine kinase inhibitors alone, 45 dasatinib, an inhibitor of both bcr-abl and Src family kinases is an obvious candidate drug.
A recent phase-II study assessed the efficacy, safety and tolerability of dasatinib in 36 patients with Ph-pos ALL who were resistant to or intolerant of imatinib. 46 Major haematological responses were achieved in 42% of patients, 67% of whom remained progression free. Over half the patients attained a complete cytogenetic response. Importantly, the presence of bcr-abl mutations conferring imatinib resistance did not preclude a response to dasatinib. Response duration was 1.9-8.7 months in this very high risk group of patients.
In conclusion, it is likely that tyrosine and Src family kinase inhibitors will play a role in the application of HSCT in Ph-pos ALL, likely facilitating HSCT by increasing CR rates, rather than obviating the need for HSCT. Current data appear to support a role for of tyrosine kinase inhibitors both during induction and post-HSCT. However, these data should be interpreted with caution, as no randomized studies have been carried out.
Summary
Patients with Ph-pos ALL should be entered into clinical studies wherever possible. Outside a clinical study, patients with a matched sibling donor should be treated with an allo HSCT with a TBI-based conditioning regimen, if they are under the age of 40, if no sibling donor is available, a wellmatched unrelated donor is a reasonable substitute. Myeloablative therapy and allo HSCT should be used with great caution in older patients. An upper age limit for this procedure is not clear for Ph-pos ALL. Although randomized controlled study evidence is completely lacking, the very high CR rates and lack of significant additional toxicity observed with tyrosine kinase inhibitors when combined with chemotherapy would make it hard to omit these drugs from induction therapy. Their role post-HSCT is less clear. In children, with Ph-pos ALL, umbilical cord blood represents a reasonable source of stem cells, in the absence of a sibling or MUD. There is currently no evidence to suggest that RIC allo HSCT is appropriate in this setting. The results of several ongoing clinical studies would consolidate our knowledge of how best to use HSCT and tyrosine and Src kinase inhibitors in Ph-pos ALL. Outside a clinical study, imatinib could be appropriately recommended for addition to induction chemotherapy with the expectation of increasing the likelihood of CR without significantly increasing toxicity. However, long-term survival benefit in Ph-pos ALL cannot yet be ascribed to the use of any tyrosine kinase inhibitors.
